AstraZeneca is planning to outsource all drug manufacturing activities within 10 years, according to a company statement. “Manufacturing for AstraZeneca is not a core activity,” said David Smith, AstraZeneca’s executive vice-president of operations. “AstraZeneca is about innovation and brand-building. There are lots of people and organizations that can manufacture better than we can,” Mr. Smith said. Mr. Smith is leading restructuring initiatives in an effort t...